article thumbnail

Side Effects are Limiting GLP-1 Drug Efficacy: How Can Personalization Offer a Solution?

MedCity News

By integrating digitization and machine learning, there is an opportunity to deliver personalized care to all patients and scale precision dosing with minimal physician involvement, maximizing the effectiveness and accessibility of these drugs. appeared first on MedCity News.

article thumbnail

Drug side effects should be easier to understand

World of DTC Marketing

According to the AMA one of the key reasons for non-adherence is that patients may be frightened of potential side effects. Additionally, patients report not taking their medication because they may have witnessed side effects experienced by a friend or family member who was taking the same or similar medication.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Serious Side Effect Sidelines Gene-Edited Sickle Cell Therapy from Graphite Bio

MedCity News

Graphite Bio voluntarily paused a Phase 1/2 test of its gene-edited therapy for sickle cell disease after the first patient in the study developed a serious blood complication. The setback will also delay plans to reach the clinic with another genetic medicine in its pipeline.

article thumbnail

Novo’s obesity drug has serious warnings and barriers to overcome

World of DTC Marketing

SUMMARY: The media headlines promise weight loss for diabetes patients, but Norvo’s new drug is in the same class as other drugs and carries many warnings. Can diabetes patients really stay adherent to a drug for 63 weeks in which 85% of patients report GI side effects and will insurance cover the cost?

article thumbnail

FDA Nod in Duchenne Helps Wider Swath of Patients With the Rare Muscle Disease

MedCity News

Corticosteroids are a standard first-line treatment for Duchenne muscular dystrophy, but these drugs have many side effects. FDA approval of Italfarmaco’s Duvyzat is the first nonsteroidal drug to pass the agency’s regulatory bar for treating this rare disease.

article thumbnail

BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings

PharmaVoice

With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.

article thumbnail

Can Herbal Alternatives Ease the Economic Burden of Weight Loss Drugs?

MedCity News

For patients who may be unable to afford the high cost of GLP-1 obesity drugs or are worried about the side effects, it’s important for healthcare providers to offer education on herbal alternatives and consider these as part of the broader treatment conversation. appeared first on MedCity News.